Crossing the minefi eld of disease names
Communities, nations, and economic sectors sometimes experience the negative consequences of being associated with the name of a disease. For example, the original naming of AIDS as "gay-related immune defi ciency" contributed to a strong and enduring stigmatisation of the gay community. A more recent example is the 2009 pandemic of so-called swine fl u: despite the fact that disease transmission was human-to-human and pigs were only associated with the origin of the outbreak, the name created widespread fear of possible infection by contact with pigs. This fear resulted in a massive drop in pork consumption and huge losses for pig breeders, and, without any justifi able medical ground, authorities slaughtered the entire pig population in Egypt.
In an eff ort to prevent similar situations, on May 8, 2015, WHO issued best practice guidelines for the naming of new human infectious diseases. Clear guidelines in this area have not been defi ned before, and WHO produced these recommendations after considering a few diff erent ideas, such as naming new diseases after mythological characters or assigning each new disease a number or a letter.
The WHO guidelines state that the name of new human infections and diseases should be based on generic symptoms (eg, respiratory syndrome, diarrhoea) and, when robust information is available, a more specifi c reference to degree of severity (eg, severe, seasonal), population aff ected (eg, neonatal, maternal), and pathogen (eg, coronavirus, Borrelia) could be included. Acronyms are encouraged because they are simple; however, in 2003 the acronym SARS (severe acute respiratory syndrome), which complies with the new guidelines, proved controversial because it generated a negative association with the Hong Kong Special Administrative Region (SAR). The new guidelines also state the name of new diseases should not include geographical names (eg, Lyme disease, Marburg haemorragic fever), animal references (eg, avian infl uenza, mad cow disease), people's names (eg, Chagas disease), references to specifi c groups (eg, Legionnaires' disease), and terms that incite undue fear (eg, fatal, unknown) .
The WHO guidelines apply only to new infections, syndromes, and diseases that have never been recognised or reported before in human beings, that have a potential public health impact, and for which there is no disease name in common use. They do not apply to diseases that are already established, so names such as Rocky Mountain spotted fever and Crimean-Congo haemorrhagic fever will not disappear.
The publication of the guidelines has sparked debate in the scientifi c community-in particular, some have expressed worries that WHO is applying political correctness, and that the new guidelines will make distinguishing diseases diffi cult by reducing the amount of useful and characterising information that a name quickly provides. Some questions remain open. Is the real priority of naming diseases providing useful information or avoiding causing off ence? How many "acute respiratory syndromes" can exist without generating confusion? Will the application of the WHO guidelines under the one size fi ts all principle be detrimental for cases in which details such as geographical references would be essential for defi ning a disease? And how would the guidelines have dealt with one of the most controversial namings of recent years, New Delhi metallo-β-lactamase 1 (NDM-1), because this is an enzyme conferring antibiotic resistance, not a disease?
The WHO guidelines are only a suggestion for best practice and do not replace the WHO International Classifi cation of Diseases (ICD); thus, they are not mandatory and there is room for fl exibility. Moreover, the initial name of a disease is often given by people outside the scientifi c community, so the actual application and results of the new best practices remains uncertain. What the WHO recommendations have correctly highlighted is inaccuracy in naming some diseases in the past and that attention is warranted. Nevertheless, the name of a disease alone is not responsible for generating unjustifi ed fears and stigmatisation: these result from a lack of correct general information about the disease and its transmission. This is the area in which health agencies should concentrate their eff orts and put their expertise to use when new diseases appear. The provision of appropriate education on new diseases to both specialised and general audiences is crucial to avoid panic and stigmatisation, independently from the disease name. ■ The Lancet Infectious Diseases For more on the WHO guidelines on naming new diseases see http://who. int/mediacentre/news/ notes/2015/naming-newdiseases/en/
